ClinicalTrials.gg
TerminatedNCT05196191Updated Mar 1, 2024

Wound Healing Following Penile Prosthesis Implant

An interventional study of VIAGENEX Max and Hibiclens wash in Erectile Dysfunction, sponsored by VIVEX Biologics, Inc.. Terminated at 1 site in United States. Open to male participants aged 30 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-01.

Sponsored by VIVEX Biologics, Inc. · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 180 studies in Erectile Dysfunction with a site in United States — 26 open to participants now, 31 under way, 3 of them phase 3. Erectile Dysfunction · United States.

Enrollment
112th of 164
32 · median 75
Started
2022
with 7 others
No phase
62 of 180
16 open now
Registered
142nd of 180
by date

Among the 180 studies in Erectile Dysfunction with a site in United States, this one is the 112th largest by enrollment of the 164 interventional ones that give a count, is one of 8 that started in 2022, is one of 62 with no phase, and was the 142nd registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

26 of the 180 studies in Erectile Dysfunction with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 30 Years to 70 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies in Erectile Dysfunction with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on men undergoing penile implant surgery for the first time. The patients are randomized in a 2:1 ratio of active to sham treatment groups.

Read the detailed description

Erectile Dysfunction (ED) is a condition with an inability to develop or maintain an erection of the penis upon sexual stimulation. It occurs in association with aging, chronic illnesses and various modifiable risk factors. Amongst the modifiable risk factors, ED shares the most common risk factors with Coronary Artery Disease (CAD) which are smoking, hypertension and hyperlipidemia. Even though it is not a part of normal aging, it is seen in 52% of men in the age group 40 to 70 years, with a higher rate in the men more than 70 years.

VIAGENEX Max is a semi-transparent, collagenous membrane intended for soft tissue barrier or wound covering, derived from umbilical cord membrane. A total of 50 subjects with ED meeting the eligibility criteria will be randomized. The treatment graft will be placed into the wound at time of surgery. The treatment group will receive the VIAGENEX graft and the sham group will receive the standard of care for this surgery.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

Keywords

  • Viagenex Max
  • penile implant
  • erectile dysfunction
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient must be willing and able to provide
  • The patient is a male between >/= 30 and =/\< 70 years of age
  • The patient has ED based of International Index of Erectile Dysfunction (IIEF) scores
  • The patient has been in a stable relationship for over 3 months prior to enrollment
  • A minimum of 2 sexual attempts per month for at least one month prior to enrollment - as documented by IIEF
  • The patient is suffering from erectile dysfunction and undergoing penile implant surgery for the first time
  • IIEF-EF score between 16 and 25
  • Testosterone level 300-1000 ng/dL within 1 month prior to enrollment
  • level \</= 7% within 1 month prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • The patient is currently or has participated in another study within the past three months that may interfere with the results or conclusions of this study
  • The patient is under judicial protection (prison or custody)
  • The patient is an adult under guardianship
  • The patient refuses to sign the consent
  • History of radical prostatectomy or extensive pelvic surgery
  • Evidence of venous leak
  • Past radiation therapy of the pelvic region within 12 months prior to enrollment
  • Recovering from any cancer within 12 months prior to enrollment
  • Neurological disease such as Alzheimer's or Parkinson's disease which affects erectile function at the discretion of the investigator
  • Psychiatric diagnosis or medications such as antidepressants, anxiolytic, antipsychotic that affects erectile function or any other medications at the discretion of the investigator
  • Anatomical malformation of the penis, including Peyronie's disease
  • Testosterone level \<300 or >1000 ng/dL within 1 month prior to enrollment
  • level > 7% within 1 month prior to enrollment or history of insulin dependent diabetes
  • The patient is taking blood thinners and has an >3
  • Received shockwave treatment at least 6 months before enrollment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Viagenex Max

    VIAGENEX Max graft will be placed in the incision at the end of surgery prior to closing.

    Biological: VIAGENEX Max

  • Active comparator
    Standard of care

    Hibiclens wash will be performed.

    Procedure: Hibiclens wash

Interventions

  • BiologicalVIAGENEX Max

    Collagenous membrane derived from umbilical cord

  • ProcedureHibiclens wash

    Antiseptic skin cleanser

06

What researchers measure

Primary outcomes

  1. Penile implant activation

    Time to use implant for sexual activity

    Time frame: up to 3 months

Secondary outcomes

  1. Pain after undergoing penile prosthesis surgery

    Numerical pain scale (0=no pain to 10=worst pain) used to

    Time frame: surgery to 12 months

07

Study locations

1 site
  • Atlanta Cosmetic Urology
    Atlanta, Georgia 30305, United States
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Dec 2023, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2021
First posted
Jan 19, 2022
StartActual
Jan 3, 2022
Primary completionActual
Dec 13, 2023
CompletionActual
Dec 30, 2023
Last update
Mar 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05196191
Lead sponsor
VIVEX Biologics, Inc.
Responsible party
Sponsor
First posted
Jan 19, 2022
Start date
Jan 3, 2022
Primary completion
Dec 13, 2023
Completion
Dec 30, 2023
Last update
Mar 1, 2024

Study contacts

Tariq Hakky, MD
principal investigator · Atlanta Cosmetic Urology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion